$13.63 -$1.05 (-7.2%)

04:00 PM EDT on 10/18/19

Fate Therapeutics (NASDAQ:FATE)

CAPS Rating: 4 out of 5

Current Price $13.63 Mkt Cap $1.0B
Open $14.47 P/E Ratio 0.00
Prev. Close $14.68 Div. (Yield) $0.00 (0.0%)
Daily Range $13.61 - $14.66 Volume 583,946
52-Wk Range $11.70 - $22.82 Avg. Daily Vol. 834,311

Caps

How do you think NASDAQ:FATE will perform against the market?

Add Stock to CAPS Watchlist

All Players

30 Outperform
3 Underperform
 

All-Star Players

6 Outperform
2 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:FATE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:FATE VS S&P 500 (SPY)

NASDAQ:FATE Summary

Fools bullish on NASDAQ:FATE are also bullish on:

Fools bearish on NASDAQ:FATE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about FATE.

Recs

0
Member Avatar shanelofgren (< 20) Submitted: 9/25/2018 10:15:15 AM : Outperform Start Price: $9.49 NASDAQ:FATE Score: +29.48

Bet on iPSC derived T cells for adoptive cell therapy.

Recs

0
Member Avatar NoPlaceLikeHome (41.55) Submitted: 3/9/2017 10:28:18 AM : Outperform Start Price: $4.09 NASDAQ:FATE Score: +207.75

With a phase 3 trial that can support an FDA application for approval of Zilretta, a non-opioid therapy for knee pain in osteoarthritis patients, under their belt, they are on the road to final approval. Long story short, if it gets the FDA green light, 10% market penetration is over $1B in revenue. It is non-opiod which means prescribers and patients do not have to hassle with increased scrutiny writing and filling scripts and I believe that will make market penetration very easy. At under $200 million in market cap and a $1B+ opportunity, I can't pass up the risk/reward. Buy!!

Recs

0
Member Avatar oscillation (68.45) Submitted: 2/11/2016 1:26:54 PM : Outperform Start Price: $1.72 NASDAQ:FATE Score: +631.44

nev

Leaderboard

Find the members with the highest scoring picks in FATE.

Score Leader

stainsolution

stainsolution (< 20) Score: +716.30

The Score Leader is the player with the highest score across all their picks in FATE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
stainsolution < 20 2/17/2016 Outperform 5Y $1.57 +770.93% +54.63% +716.30 0 Comment
oscillation 68.45 2/11/2016 Outperform 5Y $1.72 +694.75% +63.31% +631.44 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. biznessdoc 62.33 8/15/2016 Outperform 5Y $2.57 +430.35% +36.24% +394.11 0 Comment
portefeuille2 98.63 8/17/2016 Outperform 5Y $2.65 +414.34% +36.80% +377.54 0 Comment
shonny2 < 20 2/6/2017 Outperform 5Y $2.87 +374.91% +30.30% +344.61 0 Comment
NoPlaceLikeHome 41.55 3/9/2017 Outperform 5Y $4.09 +233.66% +25.91% +207.75 3 Comments
Under5 < 20 11/16/2017 Outperform 5Y $4.40 +209.77% +15.26% +194.51 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. TruffelPig < 20 3/1/2017 Outperform 5Y $4.40 +209.77% +25.10% +184.68 0 Comment
skellsmother < 20 11/11/2013 Outperform 1Y $4.45 +206.29% +68.20% +138.09 1 Comment
cyberterrorist < 20 11/12/2013 Outperform 1Y $4.51 +202.22% +68.54% +133.67 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackWedbush 88.34 10/28/2013 Outperform NS $7.10 +91.97% +69.55% +22.42 0 Comment